BAP1 |
Tumor suppressor |
Lung, Osteosarcoma, Colon |
DNA double-strand repair |
In vitro |
[80,81,82] |
|
Tumor suppressor |
Renal |
Ferroptosis signaling |
In vitro |
[83] |
USP7 |
Oncogene |
Cervical |
Self-renewal; Foxp3 signaling |
In vitro |
[84] |
|
Oncogene |
Non-small cell lung |
Immune Response; Foxp3 signaling |
In vitro |
[85] |
|
Oncogene |
Lung |
p53 signaling |
In vitro, in vivo |
[86] |
USP22 |
Oncogene |
Lung |
Cell Cycle |
In vitro |
[87] |
|
Oncogene |
Lung adenocarcinoma |
EGFR-TKI resistance |
In vitro, in vivo |
[88] |
|
Oncogene |
Colon |
CCNB1 signaling |
In vitro, in vivo |
[89] |
|
Oncogene |
Glioblastoma |
KDM1A signaling |
In vitro, in vivo |
[90] |
UCHL1 |
Oncogene |
Breast |
Drug resistance; Invasion/migration |
In vitro |
[91] |
Ataxin 3 |
Oncogene |
Breast, Osteosarcoma, Cervical, Colorectal |
DNA |
In vitro |
[92] |
|
Oncogene |
Testicular |
mTOR/Akt signaling |
In vitro |
[93] |
PSMD11 |
Oncogene |
Cervical. Osteosarcoma |
DNA damage response |
In vitro |
[94] |
|
Oncogene |
Lung, Prostate, Colorectal, Breast, Cervix |
Cell cycle |
In vitro |
[95] |
|
Oncogene |
Liver |
E2F1 signaling |
In vitro, in vivo |
[96] |
A20 |
Tumor suppressor |
Colorectal |
Apoptosis signaling |
In vitro |
[97] |
|
Tumor suppressor |
Diffuse large B-cell lymphoma |
NF-κβ signaling |
In vitro |
[98] |
|
Tumor suppressor |
Sarcoma |
NF-κβ signaling |
In vitro |
[99] |